Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Pituitary Neoplasms 4Nelson Syndrome 2Multiple Myeloma 2Carcinoma, Hepatocellular 2Carcinoid Tumor 2ACTH Syndrome, Ectopic 2Uveal Melanoma 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Sarcoma, Synovial 1Prostatic Neoplasms 1Prolactin-Producing Pituitary Tumor 1Primary Inoperable Thymoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pituitary ACTH Hypersecretion 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Meningioma 1Lymphoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Insulinoma 1Hyperinsulinism 1

Interventions

pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Growth Disorders × pasireotide × Clear all
NCT01673646 2019-09-16

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Novartis

Phase 2 Completed
33 enrolled 24 charts
Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡